Do you want to read an article? Please log in or register.
Antifibrotic drug treatment of patients with idiopathic pulmonary fibrosis in Sweden: A registry-based observational study
Pulmonary Fibrosis
Related content
Pulmonary Fibrosis
Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation
Lancet Respir Med
Alonso-González A, Jáspez D, Lorenzo-Salazar JM, Ma SF, Strickland E, Mychaleckyj J, Kim JS, Huang Y, Adegunsoye A, Oldham JM, Stewart I, Molyneaux PL, Maher TM, Wain LV, Allen RJ, Gisli Jenkins R, Kropski JA, Yaspan B, Blackwell TS, Zhang D, Garcia CK, Martinez FJ, Noth I, Flores C
doi: 10.1016/S2213-2600(25)00045-1
Pulmonary Fibrosis
Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis
Chest
Oldham JM, Neely ML, Wojdyla DM, Gulati M, Li P, Patel DC, Palmer SM, Todd JL, Idiopathic Pulmonary Fibrosis-Prospective Outcomes Registry Investigators
doi: 10.1016/j.chest.2025.02.018
RECOMMENDED
Pulmonary Fibrosis
Lung Function Course of Patients With Pulmonary Fibrosis After Initiation of Anti-Fibrotic Treatment: Real-World Data From the Dutch National Registry
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Respirology
Platenburg MGJP, Nakshbandi G, Moor CC, van Batenburg AA, Mostard RLM, Voortman M, Moonen L, Hekelaar N, Overbeek MJ, Bogaarts B, Kramer H, Marges E, Boerrigter BB, Bresser P, Schakenraad E, van der Maten J, van der Sloot CA, Walen S, Afonso PM, Wijsenbeek MS, Grutters JC
doi: 10.1111/resp.70030
RECOMMENDED
Further Publications
Effects of home-based telerehabilitation-assisted inspiratory muscle training in patients with idiopathic pulmonary fibrosis: A randomized controlled trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Respirology
Aktan R, Tertemiz KC, Yiğit S, Özalevli S, Ozgen Alpaydin A, Uçan ES
doi: 10.1111/resp.14810
Pulmonary Fibrosis
LONGITUDE: An observational study of the long-term effectiveness of elexacaftor/tezacaftor/ivacaftor in people aged ≥12 years with cystic fibrosis using data from the United Kingdom Cystic Fibrosis Registry - 2-year analysis
J Cyst Fibros
Vega-Hernandez G, MacGregor G, Wilfin A, Adams F, Haugh C, Baxter CA, Wöhling H, Clarke SL, Charman SC, Carr SB
doi: 10.1016/j.jcf.2025.04.012
RECOMMENDED
Pulmonary Hypertension
Advanced Management of Patients Undergoing Transcatheter Treatment for Pulmonary Embolism: Evidence-Based Strategies for Optimized Patient Care
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med
Costa F, Jurado-Román A, Carciotto G, Becerra-Munoz V, Márquez DT, Götzinger F, Cerrato E, Misra S, Spissu M, Pavani M, Mennuni M, Chinchilla FC, Dominguez-Franco A, Muñoz-Garcia A, Navarrete RS, Varbella F, Salinas-Sanguino P, Secemsky EA, Mahfoud F, Micari A, Alonso-Briales JH, Navarro MJ
doi: 10.3390/jcm13247780
RECOMMENDED
Pulmonary Fibrosis
Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: a retrospective registry-based study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Med
Koziar Vašáková M, Gregor J, Mogulkoc N, Kramer MR, Lewandowska K, Šterclová M, Müller V, Slivka R, Studnicka M, Plačková M, Žurková M, Tekavec-Trkanjec J, Doubková M, Ovesná P, EMPIRE investigators
doi: 10.1016/j.rmed.2024.107791
Pulmonary Fibrosis
Real-World Safety, Tolerability and Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Final Report of Post-marketing Surveillance in Japan
★ 3
Recommended and commented by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Adv Ther
Inoue Y, Ogura T, Azuma A, Kondoh Y, Homma S, Muraishi K, Ikeda R, Ochiai K, Sugiyama Y, Nukiwa T
doi: 10.1007/s12325-024-03079-2
Pulmonary Fibrosis
Reported Adverse Events in Patients with CF Receiving Treatment with Elexacaftor/Tezacaftor/Ivacaftor: 5 Years Observational Study
J Clin Med
Lucca F, Meneghelli I, Tridello G, Buniotto F, Cucchetto G, Volpi S, Pintani E, Bezzerri V, Cipolli M
doi: 10.3390/jcm14124335